Oncologix Tech, Inc.
OCLG
$0.0001
$0.000.00%
OTC PK
| 05/31/2016 | 05/31/2015 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 58.18% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 58.18% | |||
| Cost of Revenue | -- | 65.36% | |||
| Gross Profit | -- | 35.73% | |||
| SG&A Expenses | -- | 25.60% | |||
| Depreciation & Amortization | -- | -8.26% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -- | 52.24% | |||
| Operating Income | -- | -17.88% | |||
| Income Before Tax | -- | -5.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -- | -5.70% | |||
| Earnings from Discontinued Operations | -- | -100.00% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -- | -12.19% | |||
| EBIT | -- | -17.88% | |||
| EBITDA | -- | -19.07% | |||
| EPS Basic | -- | 44.39% | |||
| Normalized Basic EPS | -- | 31.25% | |||
| EPS Diluted | -- | 44.39% | |||
| Normalized Diluted EPS | -- | 31.25% | |||
| Average Basic Shares Outstanding | -- | 96.08% | |||
| Average Diluted Shares Outstanding | -- | 96.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||